Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
The economics of developing antibacterials is a frustrating topic to address. There are unique aspects to the antibiotic market which sets it apart from other medicines, esp. the unique societal aspects of antibiotic use which go beyond the benefit to the individual. IDSA has spoken out in various publications (“Bad Continue reading It’s Not a Free-Enterprise Market, Stupid!
The cartilage damage caused by fluoroquinolones in juvenile beagle dogs is not subtle: blister formation and erosions occur in a dose-dependent fashion resulting in reversible cartilage damage. These lesions can be seen not just histologically but even macroscopically. The animals are unable to walk as weight-bearing joints are predominantly affected. Continue reading The Futile Quest of Proofing a Negative in the Presence of Overwhelming Absence of Harm
Solomkin et al. conclude that the efficacy and safety of eravacycline compares favorably to the control drug, ertapenem.[1] This top-level assessment is made with the usual caveats (insufficient statistical power, small sample size), but a few points deserve comment. Eravacycline is a fluorocycline; as a tetracycline derivative it follows into Continue reading Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study